| 1 | moderately | 2,983 |
| 2 | severely | 2,481 |
| 3 | acutely | 1,215 |
| 4 | chronically | 956 |
| 5 | mildly | 954 |
| 6 | morbidly | 655 |
| 7 | seriously | 540 |
| 8 | persistently | 448 |
| 9 | privately | 88 |
| 10 | abdominally | 81 |
| 11 | occupationally | 76 |
| 12 | massively | 62 |
| 13 | lightly | 60 |
| 14 | perinatally | 56 |
| 15 | overtly | 55 |
| 16 | intellectually | 42 |
| 17 | mild-to-moderately | 30 |
| 18 | recurrently | 28 |
| 19 | focally | 25 |
| 20 | sublethally | 20 |
| 21 | affectively | 18 |
| 22 | moderately-to-severely | 16 |
| 23 | lethally | 15 |
| 24 | moderate-to-very | 14 |
| 25 | severe/very | 13 |
| 26 | subclinically | 12 |
| 27 | overweight/ | 11 |
| 28 | parentally | 11 |
| 29 | fatally | 10 |
| 30 | non-sodium | 10 |
| 31 | darkly | 8 |
| 32 | non-morbidly | 8 |
| 33 | p.16 | 8 |
| 34 | traumatically | 8 |
| 35 | nonmorbidly | 7 |
| 36 | viscerally | 7 |
| 37 | gravely | 6 |
| 38 | non-severely | 6 |
| 39 | triple-class | 6 |
| 40 | calorically | 5 |
| 41 | chow-based | 5 |
| 42 | intractably | 5 |
| 43 | irreparably | 5 |
| 44 | ischemically | 5 |
| 45 | recidivist | 5 |
| 46 | super-super | 5 |
| 47 | 'severely | 4 |
| 48 | adequate-for-gestational-age | 4 |
| 49 | cariously | 4 |
| 50 | cytoplasmically | 4 |
| 51 | duodenally | 4 |
| 52 | erosively | 4 |
| 53 | esd-derived | 4 |
| 54 | h2o2/hcl | 4 |
| 55 | infection-precipitated | 4 |
| 56 | mild-moderately | 4 |
| 57 | new/newly | 4 |
| 58 | pleasantly | 4 |
| 59 | severe-to-very | 4 |
| 60 | spousally | 4 |
| 61 | sub-chronically | 4 |
| 62 | subcritically | 4 |
| 63 | transductants | 4 |
| 64 | age-appropriately | 3 |
| 65 | fall-prone | 3 |
| 66 | floridly | 3 |
| 67 | infra-auricular | 3 |
| 68 | m-deep | 3 |
| 69 | mildly/moderately | 3 |
| 70 | moderate/ | 3 |
| 71 | never-medicated | 3 |
| 72 | non-intellectually | 3 |
| 73 | non-previously | 3 |
| 74 | overweight/mildly | 3 |
| 75 | severly | 3 |
| 76 | supersuper | 3 |
| 77 | tb/hiv-1 | 3 |
| 78 | 4296 | 2 |
| 79 | 5026 | 2 |
| 80 | 8175 | 2 |
| 81 | a-308 | 2 |
| 82 | art-controlled | 2 |
| 83 | asymptomatic/minimally | 2 |
| 84 | consanguineously | 2 |
| 85 | endogenomorphically | 2 |
| 86 | endophytically | 2 |
| 87 | intrahepatically | 2 |
| 88 | leukotriene-responsive | 2 |
| 89 | mildly-moderately | 2 |
| 90 | moderate-to- | 2 |
| 91 | molsidomine-treated | 2 |
| 92 | myocardially | 2 |
| 93 | neuro-asymptomatic | 2 |
| 94 | neurourologically | 2 |
| 95 | nonseverely | 2 |
| 96 | nonshock | 2 |
| 97 | ocularly | 2 |
| 98 | pauci | 2 |
| 99 | pervasively | 2 |
| 100 | postischemically | 2 |
| 101 | progression/relapse | 2 |
| 102 | renin-induced | 2 |
| 103 | supermorbidly | 2 |
| 104 | sw-b | 2 |
| 105 | ∆mfigf | 2 |
| 106 | -dependently | 1 |
| 107 | 10,962 | 1 |
| 108 | 11,270 | 1 |
| 109 | 114/187 | 1 |
| 110 | 12,197 | 1 |
| 111 | 13,802 | 1 |
| 112 | 134,596 | 1 |
| 113 | 15,851 | 1 |
| 114 | 16.5-month | 1 |
| 115 | 17,952 | 1 |
| 116 | 18-80-year-old | 1 |
| 117 | 18-oh | 1 |
| 118 | 19,136 | 1 |
| 119 | 2,357,942 | 1 |
| 120 | 2,961 | 1 |
| 121 | 20,023 | 1 |
| 122 | 20,328 | 1 |
| 123 | 20-mmol/l | 1 |
| 124 | 21,152 | 1 |
| 125 | 21,204 | 1 |
| 126 | 21,986 | 1 |
| 127 | 22,842,778 | 1 |
| 128 | 246,244 | 1 |
| 129 | 26-yr-old | 1 |
| 130 | 265/461 | 1 |
| 131 | 2k/1c | 1 |
| 132 | 3-ap-induced | 1 |
| 133 | 3.0-ha | 1 |
| 134 | 34,538 | 1 |
| 135 | 35mg/gc | 1 |
| 136 | 37,225 | 1 |
| 137 | 3768 | 1 |
| 138 | 38.546 | 1 |
| 139 | 38/ | 1 |
| 140 | 3=consistently | 1 |
| 141 | 4,461 | 1 |
| 142 | 4,734 | 1 |
| 143 | 4,798 | 1 |
| 144 | 4-pyridinecarboxylate | 1 |
| 145 | 40,492 | 1 |
| 146 | 41,007 | 1 |
| 147 | 43,965 | 1 |
| 148 | 4348 | 1 |
| 149 | 43mg/gc | 1 |
| 150 | 45,117 | 1 |
| 151 | 45/68 | 1 |
| 152 | 47,033 | 1 |
| 153 | 48,277 | 1 |
| 154 | 50,685 | 1 |
| 155 | 54/120 | 1 |
| 156 | 55569 | 1 |
| 157 | 6-in | 1 |
| 158 | 6.7mg/kgc | 1 |
| 159 | 6385 | 1 |
| 160 | 66/80 | 1 |
| 161 | 6623 | 1 |
| 162 | 7,872 | 1 |
| 163 | 8,308 | 1 |
| 164 | 8065 | 1 |
| 165 | 86,721 | 1 |
| 166 | 9,294 | 1 |
| 167 | 9,687 | 1 |
| 168 | 9/500 | 1 |
| 169 | =0.2mm | 1 |
| 170 | a'basal | 1 |
| 171 | a-/mild | 1 |
| 172 | anxiety-despite | 1 |
| 173 | artificially-fed | 1 |
| 174 | blood-alcohol-positive | 1 |
| 175 | bowel-barrier-function | 1 |
| 176 | carbon/flax | 1 |
| 177 | chamber-specifically | 1 |
| 178 | civet | 1 |
| 179 | clinic-attending | 1 |
| 180 | conducted.200 | 1 |
| 181 | controls.ha/cmc | 1 |
| 182 | cy-induced | 1 |
| 183 | cycloheximide-induced | 1 |
| 184 | dam-maintained | 1 |
| 185 | deaf- | 1 |
| 186 | deterioration-an | 1 |
| 187 | dimpled | 1 |
| 188 | disease-inherent | 1 |
| 189 | disproportionably | 1 |
| 190 | dose-reducing | 1 |
| 191 | dsm-iii-r/iv-established | 1 |
| 192 | early/mildly | 1 |
| 193 | electric-field-controlled | 1 |
| 194 | electrolysed | 1 |
| 195 | entitling | 1 |
| 196 | exacerbation-prone | 1 |
| 197 | exposure.more | 1 |
| 198 | fundectomy-induced | 1 |
| 199 | fut10-mirnas | 1 |
| 200 | ghulam | 1 |
| 201 | h-in | 1 |
| 202 | hakeem | 1 |
| 203 | haplotype-associated | 1 |
| 204 | hdp-related | 1 |
| 205 | hemizygote | 1 |
| 206 | hepatopathic | 1 |
| 207 | hiv-1/tuberculosis | 1 |
| 208 | hiv-pos | 1 |
| 209 | hta-treated | 1 |
| 210 | hypertrophy-induced | 1 |
| 211 | ido/3haa | 1 |
| 212 | increasinglyly | 1 |
| 213 | leptospirosis-induced | 1 |
| 214 | lhrh-dependent | 1 |
| 215 | low-to-moderately | 1 |
| 216 | lpb-related | 1 |
| 217 | maritally | 1 |
| 218 | mb-cotreatment | 1 |
| 219 | medicare- | 1 |
| 220 | mesosystolic | 1 |
| 221 | metabolism-immune | 1 |
| 222 | methamphetamine-using | 1 |
| 223 | metoprotol | 1 |
| 224 | midly | 1 |
| 225 | mildy | 1 |
| 226 | minimally/mildly | 1 |
| 227 | mir374b | 1 |
| 228 | moderate-very | 1 |
| 229 | moderately-severely | 1 |
| 230 | mono/oligoclonally | 1 |
| 231 | non-cognitively | 1 |
| 232 | non-counseled | 1 |
| 233 | non-endogenously | 1 |
| 234 | non-mhc | 1 |
| 235 | non-pcv2 | 1 |
| 236 | non-psychiatrically | 1 |
| 237 | non-supplementation/ | 1 |
| 238 | nonaids | 1 |
| 239 | nonhost | 1 |
| 240 | normal/mildly | 1 |
| 241 | normal/slightly | 1 |
| 242 | nucleoside-resistant | 1 |
| 243 | often-limited | 1 |
| 244 | otherwise-fit | 1 |
| 245 | parameters.49 | 1 |
| 246 | partly/completely | 1 |
| 247 | placebo.betamimetics | 1 |
| 248 | plastically | 1 |
| 249 | post-fbs | 1 |
| 250 | post-puberty | 1 |
| 251 | pre-/post-harvest | 1 |
| 252 | preinstrumented | 1 |
| 253 | preserved/mildly | 1 |
| 254 | prior-ntd | 1 |
| 255 | ptb-6-treated | 1 |
| 256 | q/n-rich | 1 |
| 257 | radioelectric | 1 |
| 258 | random-quota | 1 |
| 259 | re-inhibits | 1 |
| 260 | remitted/recovered | 1 |
| 261 | russian-dominant | 1 |
| 262 | salens | 1 |
| 263 | sensory-incomplete | 1 |
| 264 | severe/more | 1 |
| 265 | severely-cognitively | 1 |
| 266 | severely/extremely | 1 |
| 267 | sevoflurane-propofol-remifentanil | 1 |
| 268 | shrna-stably | 1 |
| 269 | siask1 | 1 |
| 270 | splenically | 1 |
| 271 | sub-clinically | 1 |
| 272 | sub-lethally | 1 |
| 273 | subsonically | 1 |
| 274 | t1d-prone | 1 |
| 275 | testosterone-supplemented | 1 |
| 276 | tin-independent | 1 |
| 277 | tnip1-knockin | 1 |
| 278 | transitionally | 1 |
| 279 | tt-cbd | 1 |
| 280 | unremitted/unstably | 1 |
| 281 | urethane-chloralose | 1 |
| 282 | vdcp | 1 |
| 283 | voluntary-treatment-seeking | 1 |
| 1 | 'severely | 4 |
| 2 | -dependently | 1 |
| 3 | 10,962 | 1 |
| 4 | 11,270 | 1 |
| 5 | 114/187 | 1 |
| 6 | 12,197 | 1 |
| 7 | 13,802 | 1 |
| 8 | 134,596 | 1 |
| 9 | 15,851 | 1 |
| 10 | 16.5-month | 1 |
| 11 | 17,952 | 1 |
| 12 | 18-80-year-old | 1 |
| 13 | 18-oh | 1 |
| 14 | 19,136 | 1 |
| 15 | 2,357,942 | 1 |
| 16 | 2,961 | 1 |
| 17 | 20,023 | 1 |
| 18 | 20,328 | 1 |
| 19 | 20-mmol/l | 1 |
| 20 | 21,152 | 1 |
| 21 | 21,204 | 1 |
| 22 | 21,986 | 1 |
| 23 | 22,842,778 | 1 |
| 24 | 246,244 | 1 |
| 25 | 26-yr-old | 1 |
| 26 | 265/461 | 1 |
| 27 | 2k/1c | 1 |
| 28 | 3-ap-induced | 1 |
| 29 | 3.0-ha | 1 |
| 30 | 34,538 | 1 |
| 31 | 35mg/gc | 1 |
| 32 | 37,225 | 1 |
| 33 | 3768 | 1 |
| 34 | 38.546 | 1 |
| 35 | 38/ | 1 |
| 36 | 3=consistently | 1 |
| 37 | 4,461 | 1 |
| 38 | 4,734 | 1 |
| 39 | 4,798 | 1 |
| 40 | 4-pyridinecarboxylate | 1 |
| 41 | 40,492 | 1 |
| 42 | 41,007 | 1 |
| 43 | 4296 | 2 |
| 44 | 43,965 | 1 |
| 45 | 4348 | 1 |
| 46 | 43mg/gc | 1 |
| 47 | 45,117 | 1 |
| 48 | 45/68 | 1 |
| 49 | 47,033 | 1 |
| 50 | 48,277 | 1 |
| 51 | 50,685 | 1 |
| 52 | 5026 | 2 |
| 53 | 54/120 | 1 |
| 54 | 55569 | 1 |
| 55 | 6-in | 1 |
| 56 | 6.7mg/kgc | 1 |
| 57 | 6385 | 1 |
| 58 | 66/80 | 1 |
| 59 | 6623 | 1 |
| 60 | 7,872 | 1 |
| 61 | 8,308 | 1 |
| 62 | 8065 | 1 |
| 63 | 8175 | 2 |
| 64 | 86,721 | 1 |
| 65 | 9,294 | 1 |
| 66 | 9,687 | 1 |
| 67 | 9/500 | 1 |
| 68 | =0.2mm | 1 |
| 69 | a'basal | 1 |
| 70 | a-/mild | 1 |
| 71 | a-308 | 2 |
| 72 | abdominally | 81 |
| 73 | acutely | 1,215 |
| 74 | adequate-for-gestational-age | 4 |
| 75 | affectively | 18 |
| 76 | age-appropriately | 3 |
| 77 | anxiety-despite | 1 |
| 78 | art-controlled | 2 |
| 79 | artificially-fed | 1 |
| 80 | asymptomatic/minimally | 2 |
| 81 | blood-alcohol-positive | 1 |
| 82 | bowel-barrier-function | 1 |
| 83 | calorically | 5 |
| 84 | carbon/flax | 1 |
| 85 | cariously | 4 |
| 86 | chamber-specifically | 1 |
| 87 | chow-based | 5 |
| 88 | chronically | 956 |
| 89 | civet | 1 |
| 90 | clinic-attending | 1 |
| 91 | conducted.200 | 1 |
| 92 | consanguineously | 2 |
| 93 | controls.ha/cmc | 1 |
| 94 | cy-induced | 1 |
| 95 | cycloheximide-induced | 1 |
| 96 | cytoplasmically | 4 |
| 97 | dam-maintained | 1 |
| 98 | darkly | 8 |
| 99 | deaf- | 1 |
| 100 | deterioration-an | 1 |
| 101 | dimpled | 1 |
| 102 | disease-inherent | 1 |
| 103 | disproportionably | 1 |
| 104 | dose-reducing | 1 |
| 105 | dsm-iii-r/iv-established | 1 |
| 106 | duodenally | 4 |
| 107 | early/mildly | 1 |
| 108 | electric-field-controlled | 1 |
| 109 | electrolysed | 1 |
| 110 | endogenomorphically | 2 |
| 111 | endophytically | 2 |
| 112 | entitling | 1 |
| 113 | erosively | 4 |
| 114 | esd-derived | 4 |
| 115 | exacerbation-prone | 1 |
| 116 | exposure.more | 1 |
| 117 | fall-prone | 3 |
| 118 | fatally | 10 |
| 119 | floridly | 3 |
| 120 | focally | 25 |
| 121 | fundectomy-induced | 1 |
| 122 | fut10-mirnas | 1 |
| 123 | ghulam | 1 |
| 124 | gravely | 6 |
| 125 | h-in | 1 |
| 126 | h2o2/hcl | 4 |
| 127 | hakeem | 1 |
| 128 | haplotype-associated | 1 |
| 129 | hdp-related | 1 |
| 130 | hemizygote | 1 |
| 131 | hepatopathic | 1 |
| 132 | hiv-1/tuberculosis | 1 |
| 133 | hiv-pos | 1 |
| 134 | hta-treated | 1 |
| 135 | hypertrophy-induced | 1 |
| 136 | ido/3haa | 1 |
| 137 | increasinglyly | 1 |
| 138 | infection-precipitated | 4 |
| 139 | infra-auricular | 3 |
| 140 | intellectually | 42 |
| 141 | intractably | 5 |
| 142 | intrahepatically | 2 |
| 143 | irreparably | 5 |
| 144 | ischemically | 5 |
| 145 | leptospirosis-induced | 1 |
| 146 | lethally | 15 |
| 147 | leukotriene-responsive | 2 |
| 148 | lhrh-dependent | 1 |
| 149 | lightly | 60 |
| 150 | low-to-moderately | 1 |
| 151 | lpb-related | 1 |
| 152 | m-deep | 3 |
| 153 | maritally | 1 |
| 154 | massively | 62 |
| 155 | mb-cotreatment | 1 |
| 156 | medicare- | 1 |
| 157 | mesosystolic | 1 |
| 158 | metabolism-immune | 1 |
| 159 | methamphetamine-using | 1 |
| 160 | metoprotol | 1 |
| 161 | midly | 1 |
| 162 | mild-moderately | 4 |
| 163 | mild-to-moderately | 30 |
| 164 | mildly | 954 |
| 165 | mildly-moderately | 2 |
| 166 | mildly/moderately | 3 |
| 167 | mildy | 1 |
| 168 | minimally/mildly | 1 |
| 169 | mir374b | 1 |
| 170 | moderate-to- | 2 |
| 171 | moderate-to-very | 14 |
| 172 | moderate-very | 1 |
| 173 | moderate/ | 3 |
| 174 | moderately | 2,983 |
| 175 | moderately-severely | 1 |
| 176 | moderately-to-severely | 16 |
| 177 | molsidomine-treated | 2 |
| 178 | mono/oligoclonally | 1 |
| 179 | morbidly | 655 |
| 180 | myocardially | 2 |
| 181 | neuro-asymptomatic | 2 |
| 182 | neurourologically | 2 |
| 183 | never-medicated | 3 |
| 184 | new/newly | 4 |
| 185 | non-cognitively | 1 |
| 186 | non-counseled | 1 |
| 187 | non-endogenously | 1 |
| 188 | non-intellectually | 3 |
| 189 | non-mhc | 1 |
| 190 | non-morbidly | 8 |
| 191 | non-pcv2 | 1 |
| 192 | non-previously | 3 |
| 193 | non-psychiatrically | 1 |
| 194 | non-severely | 6 |
| 195 | non-sodium | 10 |
| 196 | non-supplementation/ | 1 |
| 197 | nonaids | 1 |
| 198 | nonhost | 1 |
| 199 | nonmorbidly | 7 |
| 200 | nonseverely | 2 |
| 201 | nonshock | 2 |
| 202 | normal/mildly | 1 |
| 203 | normal/slightly | 1 |
| 204 | nucleoside-resistant | 1 |
| 205 | occupationally | 76 |
| 206 | ocularly | 2 |
| 207 | often-limited | 1 |
| 208 | otherwise-fit | 1 |
| 209 | overtly | 55 |
| 210 | overweight/ | 11 |
| 211 | overweight/mildly | 3 |
| 212 | p.16 | 8 |
| 213 | parameters.49 | 1 |
| 214 | parentally | 11 |
| 215 | partly/completely | 1 |
| 216 | pauci | 2 |
| 217 | perinatally | 56 |
| 218 | persistently | 448 |
| 219 | pervasively | 2 |
| 220 | placebo.betamimetics | 1 |
| 221 | plastically | 1 |
| 222 | pleasantly | 4 |
| 223 | post-fbs | 1 |
| 224 | post-puberty | 1 |
| 225 | postischemically | 2 |
| 226 | pre-/post-harvest | 1 |
| 227 | preinstrumented | 1 |
| 228 | preserved/mildly | 1 |
| 229 | prior-ntd | 1 |
| 230 | privately | 88 |
| 231 | progression/relapse | 2 |
| 232 | ptb-6-treated | 1 |
| 233 | q/n-rich | 1 |
| 234 | radioelectric | 1 |
| 235 | random-quota | 1 |
| 236 | re-inhibits | 1 |
| 237 | recidivist | 5 |
| 238 | recurrently | 28 |
| 239 | remitted/recovered | 1 |
| 240 | renin-induced | 2 |
| 241 | russian-dominant | 1 |
| 242 | salens | 1 |
| 243 | sensory-incomplete | 1 |
| 244 | seriously | 540 |
| 245 | severe-to-very | 4 |
| 246 | severe/more | 1 |
| 247 | severe/very | 13 |
| 248 | severely | 2,481 |
| 249 | severely-cognitively | 1 |
| 250 | severely/extremely | 1 |
| 251 | severly | 3 |
| 252 | sevoflurane-propofol-remifentanil | 1 |
| 253 | shrna-stably | 1 |
| 254 | siask1 | 1 |
| 255 | splenically | 1 |
| 256 | spousally | 4 |
| 257 | sub-chronically | 4 |
| 258 | sub-clinically | 1 |
| 259 | sub-lethally | 1 |
| 260 | subclinically | 12 |
| 261 | subcritically | 4 |
| 262 | sublethally | 20 |
| 263 | subsonically | 1 |
| 264 | super-super | 5 |
| 265 | supermorbidly | 2 |
| 266 | supersuper | 3 |
| 267 | sw-b | 2 |
| 268 | t1d-prone | 1 |
| 269 | tb/hiv-1 | 3 |
| 270 | testosterone-supplemented | 1 |
| 271 | tin-independent | 1 |
| 272 | tnip1-knockin | 1 |
| 273 | transductants | 4 |
| 274 | transitionally | 1 |
| 275 | traumatically | 8 |
| 276 | triple-class | 6 |
| 277 | tt-cbd | 1 |
| 278 | unremitted/unstably | 1 |
| 279 | urethane-chloralose | 1 |
| 280 | vdcp | 1 |
| 281 | viscerally | 7 |
| 282 | voluntary-treatment-seeking | 1 |
| 283 | ∆mfigf | 2 |
| 1 | medicare- | 1 |
| 2 | deaf- | 1 |
| 3 | moderate-to- | 2 |
| 4 | 38/ | 1 |
| 5 | moderate/ | 3 |
| 6 | non-supplementation/ | 1 |
| 7 | overweight/ | 11 |
| 8 | conducted.200 | 1 |
| 9 | 9/500 | 1 |
| 10 | 54/120 | 1 |
| 11 | 11,270 | 1 |
| 12 | 66/80 | 1 |
| 13 | tb/hiv-1 | 3 |
| 14 | 86,721 | 1 |
| 15 | 15,851 | 1 |
| 16 | 4,461 | 1 |
| 17 | 265/461 | 1 |
| 18 | 2,961 | 1 |
| 19 | siask1 | 1 |
| 20 | 13,802 | 1 |
| 21 | 2,357,942 | 1 |
| 22 | 21,152 | 1 |
| 23 | 17,952 | 1 |
| 24 | 10,962 | 1 |
| 25 | 7,872 | 1 |
| 26 | 40,492 | 1 |
| 27 | non-pcv2 | 1 |
| 28 | 20,023 | 1 |
| 29 | 6623 | 1 |
| 30 | 47,033 | 1 |
| 31 | 21,204 | 1 |
| 32 | 4,734 | 1 |
| 33 | 246,244 | 1 |
| 34 | 9,294 | 1 |
| 35 | 37,225 | 1 |
| 36 | 8065 | 1 |
| 37 | 43,965 | 1 |
| 38 | 8175 | 2 |
| 39 | 6385 | 1 |
| 40 | 50,685 | 1 |
| 41 | p.16 | 8 |
| 42 | 5026 | 2 |
| 43 | 19,136 | 1 |
| 44 | 38.546 | 1 |
| 45 | 21,986 | 1 |
| 46 | 4296 | 2 |
| 47 | 134,596 | 1 |
| 48 | 41,007 | 1 |
| 49 | 45,117 | 1 |
| 50 | 48,277 | 1 |
| 51 | 114/187 | 1 |
| 52 | 9,687 | 1 |
| 53 | 12,197 | 1 |
| 54 | 8,308 | 1 |
| 55 | a-308 | 2 |
| 56 | 20,328 | 1 |
| 57 | 34,538 | 1 |
| 58 | 4348 | 1 |
| 59 | 45/68 | 1 |
| 60 | 3768 | 1 |
| 61 | 22,842,778 | 1 |
| 62 | 4,798 | 1 |
| 63 | parameters.49 | 1 |
| 64 | 55569 | 1 |
| 65 | ido/3haa | 1 |
| 66 | 3.0-ha | 1 |
| 67 | random-quota | 1 |
| 68 | sw-b | 2 |
| 69 | mir374b | 1 |
| 70 | 2k/1c | 1 |
| 71 | 43mg/gc | 1 |
| 72 | 35mg/gc | 1 |
| 73 | 6.7mg/kgc | 1 |
| 74 | non-mhc | 1 |
| 75 | hepatopathic | 1 |
| 76 | mesosystolic | 1 |
| 77 | radioelectric | 1 |
| 78 | neuro-asymptomatic | 2 |
| 79 | controls.ha/cmc | 1 |
| 80 | tt-cbd | 1 |
| 81 | cycloheximide-induced | 1 |
| 82 | renin-induced | 2 |
| 83 | 3-ap-induced | 1 |
| 84 | leptospirosis-induced | 1 |
| 85 | cy-induced | 1 |
| 86 | hypertrophy-induced | 1 |
| 87 | fundectomy-induced | 1 |
| 88 | artificially-fed | 1 |
| 89 | dsm-iii-r/iv-established | 1 |
| 90 | non-counseled | 1 |
| 91 | electric-field-controlled | 1 |
| 92 | art-controlled | 2 |
| 93 | dimpled | 1 |
| 94 | dam-maintained | 1 |
| 95 | remitted/recovered | 1 |
| 96 | chow-based | 5 |
| 97 | electrolysed | 1 |
| 98 | never-medicated | 3 |
| 99 | ptb-6-treated | 1 |
| 100 | hta-treated | 1 |
| 101 | molsidomine-treated | 2 |
| 102 | haplotype-associated | 1 |
| 103 | lpb-related | 1 |
| 104 | hdp-related | 1 |
| 105 | infection-precipitated | 4 |
| 106 | often-limited | 1 |
| 107 | testosterone-supplemented | 1 |
| 108 | preinstrumented | 1 |
| 109 | esd-derived | 4 |
| 110 | a-/mild | 1 |
| 111 | 18-80-year-old | 1 |
| 112 | 26-yr-old | 1 |
| 113 | prior-ntd | 1 |
| 114 | adequate-for-gestational-age | 4 |
| 115 | t1d-prone | 1 |
| 116 | fall-prone | 3 |
| 117 | exacerbation-prone | 1 |
| 118 | metabolism-immune | 1 |
| 119 | exposure.more | 1 |
| 120 | severe/more | 1 |
| 121 | urethane-chloralose | 1 |
| 122 | progression/relapse | 2 |
| 123 | 4-pyridinecarboxylate | 1 |
| 124 | sensory-incomplete | 1 |
| 125 | anxiety-despite | 1 |
| 126 | hemizygote | 1 |
| 127 | leukotriene-responsive | 2 |
| 128 | blood-alcohol-positive | 1 |
| 129 | ∆mfigf | 2 |
| 130 | dose-reducing | 1 |
| 131 | clinic-attending | 1 |
| 132 | voluntary-treatment-seeking | 1 |
| 133 | entitling | 1 |
| 134 | methamphetamine-using | 1 |
| 135 | q/n-rich | 1 |
| 136 | 18-oh | 1 |
| 137 | 16.5-month | 1 |
| 138 | pauci | 2 |
| 139 | nonshock | 2 |
| 140 | 20-mmol/l | 1 |
| 141 | a'basal | 1 |
| 142 | h2o2/hcl | 4 |
| 143 | sevoflurane-propofol-remifentanil | 1 |
| 144 | metoprotol | 1 |
| 145 | ghulam | 1 |
| 146 | hakeem | 1 |
| 147 | =0.2mm | 1 |
| 148 | non-sodium | 10 |
| 149 | deterioration-an | 1 |
| 150 | 6-in | 1 |
| 151 | h-in | 1 |
| 152 | tnip1-knockin | 1 |
| 153 | bowel-barrier-function | 1 |
| 154 | vdcp | 1 |
| 155 | m-deep | 3 |
| 156 | infra-auricular | 3 |
| 157 | super-super | 5 |
| 158 | supersuper | 3 |
| 159 | fut10-mirnas | 1 |
| 160 | post-fbs | 1 |
| 161 | placebo.betamimetics | 1 |
| 162 | nonaids | 1 |
| 163 | hiv-1/tuberculosis | 1 |
| 164 | salens | 1 |
| 165 | hiv-pos | 1 |
| 166 | triple-class | 6 |
| 167 | re-inhibits | 1 |
| 168 | transductants | 4 |
| 169 | civet | 1 |
| 170 | otherwise-fit | 1 |
| 171 | russian-dominant | 1 |
| 172 | nucleoside-resistant | 1 |
| 173 | lhrh-dependent | 1 |
| 174 | tin-independent | 1 |
| 175 | mb-cotreatment | 1 |
| 176 | disease-inherent | 1 |
| 177 | pre-/post-harvest | 1 |
| 178 | recidivist | 5 |
| 179 | nonhost | 1 |
| 180 | carbon/flax | 1 |
| 181 | mildy | 1 |
| 182 | disproportionably | 1 |
| 183 | irreparably | 5 |
| 184 | intractably | 5 |
| 185 | shrna-stably | 1 |
| 186 | unremitted/unstably | 1 |
| 187 | morbidly | 655 |
| 188 | non-morbidly | 8 |
| 189 | nonmorbidly | 7 |
| 190 | supermorbidly | 2 |
| 191 | midly | 1 |
| 192 | floridly | 3 |
| 193 | mildly | 954 |
| 194 | preserved/mildly | 1 |
| 195 | normal/mildly | 1 |
| 196 | overweight/mildly | 3 |
| 197 | minimally/mildly | 1 |
| 198 | early/mildly | 1 |
| 199 | severely/extremely | 1 |
| 200 | severely | 2,481 |
| 201 | 'severely | 4 |
| 202 | non-severely | 6 |
| 203 | moderately-to-severely | 16 |
| 204 | moderately-severely | 1 |
| 205 | nonseverely | 2 |
| 206 | age-appropriately | 3 |
| 207 | moderately | 2,983 |
| 208 | mild-moderately | 4 |
| 209 | mild-to-moderately | 30 |
| 210 | low-to-moderately | 1 |
| 211 | mildly-moderately | 2 |
| 212 | mildly/moderately | 3 |
| 213 | privately | 88 |
| 214 | partly/completely | 1 |
| 215 | acutely | 1,215 |
| 216 | gravely | 6 |
| 217 | pervasively | 2 |
| 218 | erosively | 4 |
| 219 | massively | 62 |
| 220 | affectively | 18 |
| 221 | non-cognitively | 1 |
| 222 | severely-cognitively | 1 |
| 223 | darkly | 8 |
| 224 | chamber-specifically | 1 |
| 225 | neurourologically | 2 |
| 226 | endogenomorphically | 2 |
| 227 | ischemically | 5 |
| 228 | postischemically | 2 |
| 229 | cytoplasmically | 4 |
| 230 | splenically | 1 |
| 231 | sub-clinically | 1 |
| 232 | subclinically | 12 |
| 233 | chronically | 956 |
| 234 | sub-chronically | 4 |
| 235 | subsonically | 1 |
| 236 | calorically | 5 |
| 237 | non-psychiatrically | 1 |
| 238 | traumatically | 8 |
| 239 | intrahepatically | 2 |
| 240 | subcritically | 4 |
| 241 | plastically | 1 |
| 242 | endophytically | 2 |
| 243 | focally | 25 |
| 244 | lethally | 15 |
| 245 | sub-lethally | 1 |
| 246 | sublethally | 20 |
| 247 | myocardially | 2 |
| 248 | asymptomatic/minimally | 2 |
| 249 | duodenally | 4 |
| 250 | abdominally | 81 |
| 251 | occupationally | 76 |
| 252 | transitionally | 1 |
| 253 | mono/oligoclonally | 1 |
| 254 | viscerally | 7 |
| 255 | spousally | 4 |
| 256 | fatally | 10 |
| 257 | perinatally | 56 |
| 258 | maritally | 1 |
| 259 | parentally | 11 |
| 260 | intellectually | 42 |
| 261 | non-intellectually | 3 |
| 262 | ocularly | 2 |
| 263 | severly | 3 |
| 264 | consanguineously | 2 |
| 265 | cariously | 4 |
| 266 | seriously | 540 |
| 267 | non-previously | 3 |
| 268 | non-endogenously | 1 |
| 269 | lightly | 60 |
| 270 | normal/slightly | 1 |
| 271 | pleasantly | 4 |
| 272 | -dependently | 1 |
| 273 | recurrently | 28 |
| 274 | 3=consistently | 1 |
| 275 | persistently | 448 |
| 276 | overtly | 55 |
| 277 | new/newly | 4 |
| 278 | increasinglyly | 1 |
| 279 | moderate-very | 1 |
| 280 | severe-to-very | 4 |
| 281 | moderate-to-very | 14 |
| 282 | severe/very | 13 |
| 283 | post-puberty | 1 |